The authors reply

Affiliations

¹ Department of Internal Medicine-Nephrology, Ohio State University, Columbus, Ohio, USA. Electronic address: Brad.Rovin@osumc.edu.
² Aurinia Pharmaceuticals Inc., Victoria Ringgold Standard Institution, Victoria, British Columbia, Canada.

Free article

Comment

Brad H Rovin et al. Kidney Int. 2019 Apr.

Free article

. 2019 Apr;95(4):992-993.

doi: 10.1016/j.kint.2018.12.010.

¹ Department of Internal Medicine-Nephrology, Ohio State University, Columbus, Ohio, USA. Electronic address: Brad.Rovin@osumc.edu.
² Aurinia Pharmaceuticals Inc., Victoria Ringgold Standard Institution, Victoria, British Columbia, Canada.

No abstract available

Comment on

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB; AURA-LV Study Group. Rovin BH, et al. Kidney Int. 2019 Jan;95(1):219-231. doi: 10.1016/j.kint.2018.08.025. Epub 2018 Nov 9. Kidney Int. 2019. PMID: 30420324 Clinical Trial.
Data monitoring committees and randomized clinical trials.
Trachtman H, Caplan AL. Trachtman H, et al. Kidney Int. 2019 Apr;95(4):992. doi: 10.1016/j.kint.2018.12.012. Kidney Int. 2019. PMID: 30904070 No abstract available.